March 2023: Kester Capital, the UK lower mid-market private equity specialist, today announced its investment in MAP Patient Access, a leader in market access consulting services to the pharmaceutical and biotech sectors.
The investment represents Kester’s fifth investment in the Life Sciences sector. It also comes at a time of continued positive momentum for Kester, having recently invested in DC Byte, a leading data centre market intelligence and analytics business, and exited Vixio, a high growth regulatory information and data provider, generating a 4.8x return, and Avania, the leading global medical technology CRO, generating a 8.4x return.
Headquartered in Cambridge, MAP is dedicated to accelerating patient access to ground-breaking medicines, devices, and diagnostics. It has a proven track record of helping its customers navigate increasingly complex healthcare reimbursement pathways, with particular expertise in rare and orphan diseases and cell and gene therapies. MAP’s integrated approach blends best-in-class consulting with membership including its proprietary digital platform, MAP Online, which provides market access intelligence to its customers.
Increasing pressure on healthcare budgets is driving higher levels of scrutiny from healthcare advisory bodies around the world and, with its deep domain expertise, MAP is well positioned to help its customers navigate these challenges. This transaction with Kester will allow MAP to invest in broadening its service offering and expand into new territories. Kester and management will also target acquisitions to accelerate the growth of the MAP platform.
Adam Maidment, Managing Partner of Kester Capital, said: “Kester has been targeting the market access and reimbursement sector for some time and we are delighted to have the opportunity to invest in MAP, one of the leading businesses in this space. We are looking forward to partnering with Dan, Christian and the existing management team to continue the growth of the business organically and through acquisition.”
Dan Spacie, CEO, said: “This deal is a significant milestone for MAP, and we are excited to be partnering with the team at Kester, an investor with a long and successful track record in the Life Sciences sector. MAP has huge potential for growth and I am looking forward to leading the organisation as we move into this next phase.”
Christian Hill, CSO & Co-founder, said: “I am excited to be working with Dan and Kester to continue MAP’s journey and I am confident that their experience and expertise, supported by an exceptional management team, will unleash the potential from the amazing foundation of patient access success we have delivered over the past decade.”